Drugs / AZLI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03219164 | Nov 2017 → May 2020 | Pseudomonas aeruginosa infectious disease, cystic fibrosis | Gilead Sciences | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZLI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03219164 ↗ |
| Route | Inhaled | “aztreonam for inhalation solution (AZLI)” NCT03219164 ↗ |